SOURCE: MdxHealth

November 29, 2012 02:50 ET

MDxHealth Announces Its Delisting From Euronext Amsterdam

IRVINE, CA, and LIEGE, BELGIUM--(Marketwire - Nov 29, 2012) - MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, currently listed on Euronext Brussels and Euronext Amsterdam, announced today that it will de-list from Euronext Amsterdam effective as of 31 December 2012. The company considers that the Euronext is one trading platform and that a double listing is not justified anymore in the view of the increased costs which it implies. The company will remain listed on Euronext Brussels and does not expect that the de-listing from Euronext Amsterdam will have an impact on the liquidity for investors and potential investors.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, the ConfirmMDx for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth website at www.mdxhealth.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

delisting from Amsterdam: http://hugin.info/137314/R/1661238/538152.pdf

Contact Information

  • For more information:
    Dr. Jan Groen
    CEO
    MDxHealth
    US: +1 949 812 6979
    BE: +32 4 364 20 70
    info@mdxhealth.com

    Mike Sinclair
    Halsin Partners
    UK: +44 20 7318 2955
    Cell: +44 7968 022075
    msinclair@halsin.com